Alnylam and Ionis: Comparing Investment Appeal in Biotech Amidst Adverse News
ALNY Alnylam Pharmaceuticals Inc
$232.68 +3.63%
View chart & analysis → 
- 1Alnylam recorded revenue of $1.17 billion in the recent quarter, a 74% increase year-over-year.
- 2Ionis saw a roughly 41% year-over-year decrease in revenue for Q2 2026, recording an adjusted quarterly loss of $57 million.
- 3Alnylam offers a more attractive risk-reward proposition than Ionis.
So what's the key point?
Alnylam's revenue grew significantly by 74% compared to last year. This means the company is a better option for seeking returns with less risk than Ionis.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.